;

Home

SARC Clinical Studies Now Recruiting

Spotlight

JULY IS SARCOMA AWARENESS MONTH

Join SARC in celebrating the achievements of sarcoma patients and caregivers, recognizing advancements in sarcoma treatments, and raising awareness of the critical need to support research in sarcoma. Follow us on social media to learn more about SARC’s impact on sarcoma research and why your donation matters.

Together, we CAN find a cure.

Support SARC Today

June 17, 2024

Research Advocacy Council Logo

Research Advocacy Council (RAC) Updates

The Research Advocacy Council is working on several projects behind the scenes, including involvement in the newest SARC clinical trial, SARC044.

June 13, 2024

Dr, Patrick Grohar

SARC037 Progress Announced at ASCO 2024

Dr. Patrick Grohar presented the SARC037 findings at ASCO 2024. The results suggest that EWS::FLI1 is a target for Ewing sarcoma and the combination of trabectedin/irinotecan is active in treatment-refractory Ewing sarcoma patients.

More SARC News
Where can I find a Sarcoma Center?

View locations
HOW CAN I PARTICIPATE IN A SARC CLINICAL TRIAL?

Find active trials that are recruiting
  • Wednesday
  • Nov 13
  • 2024
LEARN MORE


WHAT ARE SARCOMAS?

Sarcomas are uncommon and there are many different types — experts have identified more than 80 different forms — leading to significant diagnostic and therapeutic challenges. Sarcomas represent 15 to 20% of childhood cancers and 1% of adult cancers.

LEARN MORE

young child sarcoma patient

WHAT DOES SARC DO?

Founded in 2003 as a non-profit cancer research organization, SARC directly develops, sponsors, and manages research projects for pediatric and adult sarcomas. We lead domestic and international collaborative discovery, translational research, and clinical trials.

LEARN MORE

Microscope Pink

WHO PARTNERS WITH SARC?

We collaborate with the scientific research community and sarcoma centers, partner with pharmaceutical and biotech companies, and provide patients and caregivers resources and information about our work.

LEARN MORE

Back to top